Alnylam Pharmaceuticals Inc (ALNY) - News Archive

In a significant advancement in the treatment of uncontrolled hypertension, Genentech, a member of the Roche Group, and Alnylam Pharmaceuticals have announced their decision to initiate a Phase III cardiovascular outcom...

CAMBRIDGE, Massachusetts In a remarkable stride toward revolutionizing healthcare, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is setting the stage to unveil groundbreaking innovations at the forthcoming European Socie...

Alnylam Pharmaceuticals Inc. recently presented additional data from the HELIOS-B clinical trial, highlighting the significant benefits of its drug, AMVUTTRA (vutrisiran), for patients with transthyretin amyloid cardiom...

In a groundbreaking development that promises to redefine treatment standards, Alnylam Pharmaceuticals, Inc. has recently achieved a significant milestone in the realm of RNA interference (RNAi) therapeutics. The U.S. F...

Alnylam Pharmaceuticals Breakthrough Approval: AMVUTTRA for ATTR-CM Garners FDA Nod Alnylam Pharmaceuticals Leads Innovation in RNAi Therapeutics with AMVUTTRA and Promising Research on Nucresiran Alnylam Pharmaceutical...

The world of pharmaceutical science is continually evolving, bringing promising advancements that have the potential to transform patient care. In this light, Alnylam Pharmaceuticals has announced a significant mileston...

Breakthrough in RNAi Therapeutics: Alnylam s Nucresiran Shows Promise Amid Financial HurdlesIn an exciting development for the medical community, Alnylam Pharmaceuticals, Inc. a leader in RNAi therapeutics, has announce...

Alnylam Submits Supplemental New Drug Application for Vutrisiran: A Potential Game-Changer in Transthyretin Amyloidosis Treatment CAMBRIDGE, Mass. In a pivotal move for the treatment of an increasingly recognized and de...

In a significant advancement in the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) recently showcased compelling findings from the HELIOS-B Phase 3 cli...

Avances en el Tratamiento de la Amiloidosis Cardíaca ATTR: Alnylam Pharmaceuticals Presentará Resultados del Estudio de Fase 3 HELIOS-B en el Congreso de la Sociedad Europea de Cardiología 2024Cambridge, Massachusetts -...

CAMBRIDGE, Mass. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leader in RNA interference (RNAi) therapeutics, is set to unveil detailed results from its pivotal HELIOS-B Phase 3 study of vutrisiran, a novel treatment...

Alnylam Pharmaceuticals Achieves Impressive Growth in Q2 2024, Highlighting Strategic Advancements and Financial ResilienceIn a promising demonstration of financial health and strategic execution, Alnylam Pharmaceutical...

The pharmaceutical industry is highly dynamic, with stock prices being influenced by various factors including company news, market trends, and investor sentiment. Alnylam Pharmaceuticals Inc, a renowned biopharmaceutic...

Alnylam Pharmaceuticals Inc., a prominent biopharmaceutical company, has been making waves in the investment world lately. With a string of positive developments, including successful clinical trials and impressive stoc...

Alnylam Pharmaceuticals Announces Groundbreaking Phase 3 HELIOS-B Study Results for Vutrisiran CAMBRIDGE, Mass. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) , the pioneering company in RNA interference (RNAi) therapeuti...